Since the 1980s, Novo Nordisk has been at the forefront of design-driven innovation with its easy-to-use injection pens.
With its line of insulin injection pens such as the successful FlexTouch pen, initially released in 2011 and since distributed worldwide, Novo Nordisk has raised the bar in pharmaceutical design.
The design of the pens, made in close collaboration with engineers and designers, reflects the fundamental values in the Danish design DNA with its simple, human, transformative, and innovative approach to treating diabetes and other chronic conditions.
The pens are a result of Novo Nordisk’s dedicated focus to improving the lives of patients and delivering the first user-friendly, simple, and discrete injection solution. This has significantly lowered the burden of self-injecting medicine for people with diabetes and other chronic conditions.See the jury members